ACADIA Pharmaceuticals (ACAD) : The consensus on ACADIA Pharmaceuticals (ACAD) based on 6 analyst recommendation on the company stock is 1.67, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 4 which endorses a Sell on the stock. However, 4 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 2 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.
ACADIA Pharmaceuticals (ACAD) : Average target price received by ACADIA Pharmaceuticals (ACAD) is $45.83 with an expected standard deviation of $7.73. The most aggressive target on the stock is $60, whereas the most downbeat target is $39. 6 financial analysts are currently covering the stock.
Shares of ACADIA Pharmaceuticals Inc. appreciated by 6.15% during the last five trading days but lost 5.37% on a 4-week basis. ACADIA Pharmaceuticals Inc. has dropped 1.55% during the last 3-month period . Year-to-Date the stock performance stands at -3.62%. ACADIA Pharmaceuticals (NASDAQ:ACAD): stock turned positive on Tuesday. Though the stock opened at $34.6, the bulls momentum made the stock top out at $34.675 level for the day. The stock recorded a low of $34.024 and closed the trading day at $34.36, in the green by 0.12%. The total traded volume for the day was 1,242,615. The stock had closed at $34.32 in the previous days trading.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for the treatment of neurological and related central nervous system disorders. The Companys drug candidate NUPLAZID (pimavanserin) is under development for the treatment of Parkinsons disease psychosis, Alzheimers disease psychosis, Schizophrenia and Sleep disturbances. The Company is also conducting preclinical programs for alpha adrenergic agonists indicated for the treatment of chronic pain and muscarinic drugs for the treatment of glaucoma. NUPLAZID has an active ingredient pimavanserin, is a selective serotonin inverse agonist (SSIA) preferentially targeting 5-HT2A receptors that was discovered by the Company. The Company in collaboration with Allergan, has discovered and engaged in the development of small-molecule product candidates, such as alpha adrenergic agonists and muscarinic receptors.